285 related articles for article (PubMed ID: 16045689)
1. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
3. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
6. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma.
Vihinen P; Koskivuo I; Syrjänen K; Tervahartiala T; Sorsa T; Pyrhönen S
Melanoma Res; 2008 Aug; 18(4):268-73. PubMed ID: 18626311
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
8. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography.
Kurschat P; Wickenhauser C; Groth W; Krieg T; Mauch C
J Pathol; 2002 Jun; 197(2):179-87. PubMed ID: 12015741
[TBL] [Abstract][Full Text] [Related]
9. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Stoebner PE; Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Dandurand M; Joujoux JM; Bureau JP; Meunier L
Br J Dermatol; 2005 May; 152(5):948-53. PubMed ID: 15888151
[TBL] [Abstract][Full Text] [Related]
10. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma.
El-Shabrawi Y; Ardjomand N; Radner H; Ardjomand N
J Pathol; 2001 Jun; 194(2):201-6. PubMed ID: 11400149
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
13. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
Airola K; Karonen T; Vaalamo M; Lehti K; Lohi J; Kariniemi AL; Keski-Oja J; Saarialho-Kere UK
Br J Cancer; 1999 May; 80(5-6):733-43. PubMed ID: 10360651
[TBL] [Abstract][Full Text] [Related]
14. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
15. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
16. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
17. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Pelletier F; Bermont L; Puzenat E; Blanc D; Cairey-Remonnay S; Mougin C; Laurent R; Humbert P; Aubin F
Br J Dermatol; 2005 Apr; 152(4):685-9. PubMed ID: 15840099
[TBL] [Abstract][Full Text] [Related]
18. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
Docampo MJ; Cabrera J; Rabanal RM; Bassols A
Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
[TBL] [Abstract][Full Text] [Related]
20. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer.
Bogusiewicz M; Stryjecka-Zimmer M; Szymanski M; Rechberger T; Golabek W
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):132-6. PubMed ID: 12574771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
